Eph Receptors As Oncotargets

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Nov 16

PMID 29137214

Citations 5

Authors

Sara Charmsaz

Andrew W Boyd

Affiliations

Soon will be listed here.

Citing Articles

EphA2 regulates vascular permeability and prostate cancer metastasis via modulation of cell junction protein phosphorylation.

Offenhauser C, Dave K, Beckett K, Smith F, Jayakody B, Cooper L Oncogene. 2024; 44(4):208-227.

PMID: 39511410 PMC: 11753358. DOI: 10.1038/s41388-024-03206-x.

Oncological Ligand-Target Binding Systems and Developmental Approaches for Cancer Theranostics.

Jeevanandam J, Sabbih G, Tan K, Danquah M Mol Biotechnol. 2021; 63(3):167-183.

PMID: 33423212 DOI: 10.1007/s12033-020-00296-2.

Silencing of COPB2 inhibits the proliferation of gastric cancer cells and induces apoptosis via suppression of the RTK signaling pathway.

An C, Li H, Zhang X, Wang J, Qiang Y, Ye X Int J Oncol. 2019; 54(4):1195-1208.

PMID: 30968146 PMC: 6411345. DOI: 10.3892/ijo.2019.4717.

Therapeutic potential of targeting the Eph/ephrin signaling complex.

Saha N, Robev D, Mason E, Himanen J, Nikolov D Int J Biochem Cell Biol. 2018; 105:123-133.

PMID: 30343150 PMC: 6457248. DOI: 10.1016/j.biocel.2018.10.006.

Differential Expression Patterns of Eph Receptors and Ephrin Ligands in Human Cancers.

Kou C, Kandpal R Biomed Res Int. 2018; 2018:7390104.

PMID: 29682554 PMC: 5851329. DOI: 10.1155/2018/7390104.

References

Day B, Stringer B, Al-Ejeh F, Ting M, Wilson J, Ensbey K . EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme. Cancer Cell. 2013; 23(2):238-48. DOI: 10.1016/j.ccr.2013.01.007. View

Swords R, Greenberg P, Wei A, Durrant S, Advani A, Hertzberg M . KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study. Leuk Res. 2016; 50:123-131. DOI: 10.1016/j.leukres.2016.09.012. View

Charmsaz S, Beckett K, Smith F, Bruedigam C, Moore A, Al-Ejeh F . EphA2 Is a Therapy Target in EphA2-Positive Leukemias but Is Not Essential for Normal Hematopoiesis or Leukemia. PLoS One. 2015; 10(6):e0130692. PMC: 4470658. DOI: 10.1371/journal.pone.0130692. View

Charmsaz S, Scott A, Boyd A . Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors. Exp Hematol. 2017; 54:31-39. DOI: 10.1016/j.exphem.2017.07.003. View

Tandon M, Vemula S, Mittal S . Emerging strategies for EphA2 receptor targeting for cancer therapeutics. Expert Opin Ther Targets. 2010; 15(1):31-51. PMC: 3016619. DOI: 10.1517/14728222.2011.538682. View